Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma

Suramin is an antitrypanosomal agent with antineoplastic activity, but with serious systemic side effects. We administered Suramin intravesically to determine a concentration with low toxicity but with evidence of a pharmacodynamic effect, to recommend a dose level for phase II trials. This was an o...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Ord, J J, Streeter, E, Jones, A, Le Monnier, K, Cranston, D, Crew, J, Joel, S P, Rogers, M A, Banks, R E, Roberts, I S D, Harris, A L
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2005
Assuntos:
Clinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2361814/
https://ncbi.nlm.nih.gov/pubmed/15928663
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6602650
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados